## TABLE OF CONTENTS

### COMMENTARY

129 **Evaluating Lung Cancer Screening Across Diverse Healthcare Systems: A Process Model from the Lung PROSPR Consortium**

Katharine A. Rendle, Andrea N. Burnett-Hartman, Christine Neslund-Dudas, Robert T. Greenlee, Stacey Honda, Jennifer Elston Lafata, Pamela M. Marcus, Mary E. Cooley, Anil Vachani, Rafael Meza, Caryn Oshiro, Michael J. Simoff, Mitchell D. Schnall, Elisabeth F. Beaber, V. Paul Doria-Rose, Chyke A. Doubeni, and Debra P. Ritzwoller

### MINIREVIEW

137 **E-Cigarettes and Cancer Risk**

Boris Mravec, Miroslav Tibensky, Lubica Horvathova, and Pavel Babal

### RESEARCH BRIEF

145 **Effects of Electronic Cigarette Constituents on the Human Lung: A Pilot Clinical Trial**

Min-Ae Song, Sarah A. Reisinger, Jo L. Freudenheim, Theodore M. Brasky, Ewy A. Mathé, Joseph P. McElroy, Quentin A. Nickerson, Daniel Y. Weng, Mark D. Wewers, and Peter G. Shields

### RESEARCH ARTICLES

153 **Comparison of Systemic Exposure to Toxic and/or Carcinogenic Volatile Organic Compounds (VOC) during Vaping, Smoking, and Abstention**

Gideon St. Helen, Evangelia Liakoni, Natalie Nardone, Newton Addo, Peyton Jacob III, and Neal L. Benowitz

163 **Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women**

Ming-Yue Jiang, Zeni Wu, Tingyuan Li, Lulu Yu, Shao-Kai Zhang, Xun Zhang, Pengpeng Qu, Peisong Sun, Ming-Rong Xi, Xin Liu, Guangdong Liao, Lixin Sun, Yongzhen Zhang, Wen Chen, and You-Lin Qiao

173 **A Multistage Murine Breast Cancer Model Reveals Long-Lived Premalignant Clones Refractory to Parity-Induced Protection**

Shuo Li, Shelley A. Gestl, and Edward J. Gunther

185 **Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model**

Venkateshwar Madka, Gaurav Kumar, Gopal Pathuri, Yuting Zhang, Stanley Lightfoot, Adam S. Asch, Altaf Mohammed, Vernon E. Steele, and Chinthalapally V. Rao

195 **Metformin Use and the Risk of Cancer in Patients with Diabetes: A Nationwide Sample Cohort Study**

Tak Kyu Oh and In-Ae Song

203 **A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index**


AC icon indicates AuthorChoice

For more information please visit [www.aacrjournals.org](http://www.aacrjournals.org)
Environmental exposures that increase breast cancer risk typically occur decades prior to disease onset, reinforcing the concept that breast cancers evolve from long-lived premalignant clones. The biological description of these premalignant clones is incomplete, hindering efforts to improve breast cancer chemoprevention strategies. To create an experimental framework for isolating and targeting premalignant breast disease, Li and colleagues (in a study beginning on page 173) drew inspiration from classical mouse models of multistage skin carcinogenesis. By combining chemical carcinogenesis with an inducible transgenic mouse model of breast cancer, mammary carcinogenesis was resolved into discrete initiation and progression stages. Mechanistically, carcinogen-induced HRas^{G12L} mutations mark the clonal link between long-lived, subclinical mammary lesions and subsequent transgene-driven mammary cancers. The cover image shows a carmine-stained whole-mount of a mammary gland from a carcinogen-exposed mouse. The gland, harvested after two weeks of transgene-driven activation of the Wnt pathway, harbors a focal ductal lesion progressing toward overt mammary cancer amid a background of diffuse Wnt-driven hyperplasia. Variations on this multistage modeling strategy may help identify and validate novel cellular and molecular targets for breast cancer chemoprevention.